Compare SHEN & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHEN | DRTS |
|---|---|---|
| Founded | 1902 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 634.6M | 607.1M |
| IPO Year | 1994 | N/A |
| Metric | SHEN | DRTS |
|---|---|---|
| Price | $13.94 | $7.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $26.00 | $9.50 |
| AVG Volume (30 Days) | 226.4K | ★ 313.7K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $357,854,000.00 | N/A |
| Revenue This Year | $10.77 | N/A |
| Revenue Next Year | $4.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.08 | N/A |
| 52 Week Low | $9.67 | $2.30 |
| 52 Week High | $15.84 | $8.60 |
| Indicator | SHEN | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 80.08 | 60.08 |
| Support Level | $12.80 | $6.57 |
| Resistance Level | $14.41 | N/A |
| Average True Range (ATR) | 0.42 | 0.51 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 81.65 | 68.66 |
Shenandoah Telecommunications Company, with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.